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A B S T R A C T
The mediator of dioxin toxicity, aryl hydrocarbon receptor (AHR), has also important physiological functions.
Selective AHR modulators (SAHRMs) share some effects of dioxins, except for their marked toxicity. We recently
characterised toxicologically two novel SAHRMs, prodrugs IMA-08401 and IMA-07101 in rats, demonstrating
that they are far less deleterious than the most toxic AHR-agonist, TCDD. Here, we analysed the in vitro toxicity
and in silico AHR binding of the respective active, deacetylated metabolites, IMA-06201 (N-ethyl-N-phenyl-5-
chloro-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide) and IMA-06504 (N-(4-tri-
fluoromethylphenyl)-1,2-dihydro-4-hydroxy-5-methoxy-1-methyl-2-oxo-quinoline-3-carboxamide). In H4IIE rat
hepatoma cells, IMA-06201 and IMA-06504 induced CYP1A1 with comparable potencies and efficacies to those
of TCDD. They had little effect on cell viability as assessed by LDH leakage and MTT reduction assays, and were
not mutagenic in the Ames test, but IMA-06504 elicited a maximally 2.7-fold increase in micronuclei. Molecular
docking simulations showed that similar to TCDD, they occupy the central region of AHR ligand binding cavity.
Hence, while showing low to negligible in vitro toxicity, these novel SAHRMs bind to the AHR qualitatively in a
similar fashion to TCDD, and appear comparably powerful AHR agonists. Combined with our earlier results
demonstrating that they seem considerably less toxic in vivo than TCDD, these compounds are thus highly in-
teresting new SAHRMs.
1. Introduction
The aryl hydrocarbon receptor (AHR) is an evolutionarily ancient,
ligand-activated transcription factor (Beischlag, et al. 2008). It reg-
ulates the activity of various genes in different cell types across all
vertebrates, including genes for some xenobiotic-metabolising enzymes,
“the AHR battery”. The AHR has varied, important physiological
functions, and is also well known and extensively studied as the med-
iator of toxicity induced by a class of environmental contaminants
called dioxins [polychlorinated dibenzo-para-dioxins (PCDDs), poly-
chlorinated dibenzofurans (PCDFs) and dioxin-like polychlorinated bi-
phenyls (PCBs); reviewed, for example, in (Hahn and Karchner 2011,
Mandal 2005)].
The molecular mechanism of AHR action has been revealed in detail
for transcriptional induction of the drug-metabolising enzyme CYP1A1,
which is believed to represent a more general pattern, known as the
canonical pathway of AHR signalling. In its inactive state, the AHR is
located in the cytosol in association with the chaperone proteins
HSP90, XAP2 and p23. Binding of a ligand triggers transformation in
the protein structure, causing the AHR to translocate into the nucleus.
There it sheds the cytosolic protein partners and dimerizes with a
structurally related protein, ARNT. The AHR-ARNT dimer then binds to
the DNA at specific enhancer sites called dioxin response elements
(DREs) in the promoter region of the Cyp1a1 gene. This eventually leads
to induced transcription of CYP1A1 mRNA (Ma 2011), a fairly rapid
and highly sensitive marker for AHR activation (Abraham, et al. 1988).
Although the canonical signalling pathway is in general quite well
understood, many details, especially about its regulation, are still
lacking. Furthermore, in addition to the canonical pathway, there ap-
pear to be several non-canonical pathways related to AHR function,
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which involve the AHR interacting with other transcription factors or
pathways within cells (Denison and Faber 2017, Guyot, et al. 2013).
The AHR binds numerous ligands, which have notably diverse
structures and can be of both exogenous and endogenous origin. This
promiscuity is considered to be at least partly due to differences in
binding modes to the ligand binding domain (LBD) of the AHR
(DeGroot et al., 2011). It is particularly interesting because the effects
of differential AHR modulation are highly ligand-specific (Denison and
Faber 2017) and of great variety, ranging from beneficial to extremely
toxic. Furthermore, while AHR homologues are widespread in fauna,
their functions among species vary. There are genes, such as Cyp1a1,
whose expression is modulated consistently by the AHR across species
in response to AHR modulators; however, there are also various others,
whose expression differs significantly among species, in some cases
even among strains (Denison and Faber 2017, Flaveny, et al. 2010,
Forgacs, et al. 2013, Pohjanvirta, et al. 1993, Sun, et al. 2004). The
strain and species differences appear, for a large part, to be attributable
to structural differences of the AHR (Denison, et al. 2011, Pohjanvirta,
et al. 2011). However, those may not be adequate to alone explain the
diverse outcomes of AHR modulation observed within organisms by
various AHR agonists. It is likely that differences in mechanistic steps
related to AHR ligand or DNA binding, interactions with transcriptional
co-regulators, subsequent signalling pathways, and their regulation are
also important (Bonati, et al. 2017, Gasiewicz and Henry 2011).
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the most toxic dioxin
and has, as such, been widely employed in research as a classical
compound for activation of the AHR (Van Den Berg, et al. 1998). TCDD
causes a multitude of adverse effects in laboratory animals including
hypophagia, wasting syndrome, developmental toxicity, endocrine
disruption, carcinogenicity and immunotoxicity (Pohjanvirta and
Tuomisto 1994). The current consensus is that they result from in-
appropriately persistent and untimely activation of the AHR (Bock and
Köhle 2006, Denison, et al. 2011). Interestingly, some of the biological
impacts of TCDD-induced AHR modulation are such that they would be
beneficial in the treatment of certain conditions, if toxicity could be
evaded (Vorderstrasse and Lawrence 2006, Xu, et al. 2015). Further-
more, increasing evidence is emerging about the involvement of the
AHR in normal physiological functions and in disease aetiology, parti-
cularly in relation to immunomodulation and cancer (Feng, et al. 2013,
Murray, et al. 2014, Quintana, et al. 2010, Zhu, et al. 2014).
So far, appropriate modulation of AHR activity has been shown as a
potential target for novel therapeutics in the treatment of, for instance,
cancer (Díaz-Díaz, et al. 2016, Jin, et al. 2014), multiple sclerosis (MS)
(Singh, et al. 2007), inflammatory skin diseases (Di Meglio, et al. 2014,
Haas, et al. 2016, Van Den Bogaard, et al. 2013), Crohn's disease
(Benson and Shepherd 2011) and inflammatory bowel disease
(Arsenescu, et al. 2011, Furumatsu, et al. 2011). Therefore, the AHR
appears a highly interesting target for novel therapies in several fields,
and selective AHR modulators (SAHRMs) intriguing candidates for lead
compounds. SAHRMs are a large and diverse group of both natural and
engineered molecules, which induce subsets of AHR-mediated effects,
often without the major toxic outcomes of dioxins such as TCDD. In
addition, SAHRMs could be valuable tools in further elucidating the
multifaceted physiological roles of the AHR and the underlying mole-
cular mechanisms.
We recently characterised the toxicity of two novel such SAHRMs in
Sprague Dawley (SD) rats: IMA-08401 (N-acetyl-N-phenyl-4-acetoxy-5-
chloro-1,2-dihydro-1-methyl-2-oxo-quinoline-3-carboxamide; later re-
ferred to as C2 for simplicity; Fig. 1) and IMA-07101 (N-acetyl-N-(4-
trifluoromethylphenyl)-4-acetoxy-1,2-dihydro-5-methoxy-1-methyl-2-oxo-
quinoline-3-carboxamide; later C4) (Mahiout, et al. 2017). C2 and C4
represent diacetyl prodrugs of N‑hydrogen metabolites of the im-
munomodulatory drug compounds laquinimod and tasquinimod, of
which laquinimod has been studied in phase II/III clinical trials for
treatment of MS (Polman, et al. 2005, Thöne and Linker 2016) and
Chron's disease (D'Haens, et al. 2015), and is currently in phase II
studies for treatment of Huntington's disease (Garcia-Miralles, et al.
2016). In vivo, we demonstrated that even at the highest doses practi-
cally achievable, C2 and C4 appeared considerably less toxic than TCDD
(at a some 1000-fold lower single dose) after acute and subacute (re-
peated 5-day) dosing, while acting as effective activators of the AHR, as
evaluated by Cyp1a1 gene induction (Mahiout, et al. 2017). Some major
characteristic toxicities of dioxins that C2 and C4 lacked, at least at the
dose levels tested, were hypercholesterolemia, reduced plasma thyr-
oxine levels, acute lethality, wasting syndrome, grave liver and testis
lesions, hypoglycaemia, and elevated plasma free fatty acid (FFA) levels
(Pohjanvirta, et al. 2011, Viluksela, et al. 1999). The main adverse ef-
fects seen with high doses of C2 and C4 in vivo were thymic atrophy,
alterations in serum triglyceride and 3-hydroxybutyrate levels, and
changes in liver and kidney retinol and retinyl palmitate concentrations
(Mahiout, et al. 2017). Furthermore, there were modulations in the
expression of selected genes of the AHR battery. Intriguingly, all of the
dioxin-like effects observed in vivo fell into the “type I" category pre-
viously demonstrated to be largely indifferent to structural variation at
the transactivation domain of the AHR in TCDD-treated rats
(Pohjanvirta, et al. 2011).
To gain further understanding of the effects and potency of these
compounds, in the present study we characterised in vitro effects of the
respective active, deacetylated metabolites that the prodrugs C2 and C4
readily hydrolyse to in vivo: IMA-06201 (N-ethyl-N-phenyl-5-chloro-1,2-
dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide; later C1)
and IMA-06504 (N-(4-trifluoromethylphenyl)-1,2-dihydro-4-hydroxy-5-
methoxy-1-methyl-2-oxo-quinoline-3-carboxamide; later C3). C1 and C3
are, despite being the active compounds, unsuitable for in vivo for-
mulations due to their low aqueous solubility, hence the use of the
prodrugs C2 and C4 in vivo and C1 and C3 in vitro. The chemical re-
lationships between C2, laquinimod and C1 are depicted in Fig. 2.
C1 and C3 were first assessed for their in vitro toxicity, in some cases
in parallel with TCDD, to further compare their effects. Generally,
TCDD is not overtly toxic to cultured cells in vitro, despite its drastic
effects in vivo (Beatty, et al. 1975, Knutson and Poland 1980, Schecter,
et al. 1987). However, the same could not be taken for granted for C1
and C3, particularly because in vivo, we had observed some effects with
C2 and C4 that have not been reported with TCDD. Those included a
conspicuous hyperaemia of the ears, minimal extramedullary myeloid
haematopoiesis in the liver, a reduction of serum triglycerides, and an
increase of serum 3-HB (Mahiout, et al. 2017).
Here, the endpoints included were cytotoxicity assessed by LDH
leakage assay, reduction of cell viability/metabolic activity by MTT
reduction assay, and genotoxicity by Ames and micronucleus tests.
Furthermore, the AHR activation potency and efficacy of C1 and C3
were studied by measuring CYP1A1 enzyme activity in the metaboli-
cally active rat hepatoma cell line H4IIE, and compared with those of
TCDD. We also examined the ability of a specific, ligand-selective AHR
antagonist, CH-223191, to block CYP1A1 induction by these com-
pounds. Finally, we explored and compared the abilities of C1, C3, and
TCDD to bind the rat AHR LBD using in silico molecular modelling
approaches, in order to understand differences and similarities among
the three ligands.
2. Materials and methods
2.1. Chemicals
The test compounds IMA-06201 (C1; CAS Registry Number:
879410-94-3; Fig. 1) and IMA-06504 (C3; CAS: 1373259-57-4) were
synthetized as described by Pettersson (2012). The AHR antagonist CH-
223191 (Kim, et al. 2006, Zhao, et al. 2010) was purchased from Sigma-
Aldrich (St. Louis, MO USA), and TCDD from Ufa-Institute (Ufa, Russia;
over 98% pure as assessed by gas chromatography–mass spectrometry).
Solutions of all of the test compounds were prepared by dissolving in
DMSO (Sigma-Aldrich). Dissolution of C1 and C3 stocks was aided by
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heating them in +37–65 °C or+ 65–85 °C waterbaths, respectively, for
30–60min. For the H4IIE cells, all DMSO solutions were further diluted
with cell culture medium before application to cells (final DMSO con-
centration on cells was 0.1%).
Chemicals used as positive controls included Triton X, benzo[a]
pyrene (BaP), sodium azide (NaN3), 2-aminoanthracene (2AA), and
mitomycin C (all from Sigma). Apart from Triton X, they were dissolved
in either H2O or DMSO.
2.2. Cell culture
Rat hepatoma H4IIE cells, acquired from ATCC (H-4-II-E ATCC®
CRL1548™; Manassas, VA USA), were used in all in vitro experiments,
apart from the Ames test. This cell line was selected for its highly in-
ducible expression of CYP xenobiotic-metabolising enzymes (Fujimura,
et al. 2012). In addition, it has been shown to be exceptionally re-
sponsive to CYP1A1 induction by dioxins (Bradlaw and Casterline Jr.
1979, Sawyer and Safe 1982).
The cells were cultured at 37 °C and 5% CO2 in low glucose EMEM
(ATCC) or low glucose DMEM (Gibco® DMEM, Thermo Fisher
Scientific, Paisley, Scotland, UK), depending on the medium used in the
following experiment. Both media were supplemented with 10% FBS
(Sigma-Aldrich) for cell culturing. Cell passages from 2 to 6 were used
for the experiments. MycoAlert™ Mycoplasma Detection Kit (Lonza
Group Ltd., Basel, Switzerland) was used periodically to ensure that the
cells used in the experiments were free of infection.
2.3. LDH leakage assay
Cytotoxicity of C1, C3 and TCDD was assessed in H4IIE cells using
Cytotoxicity Detection Kit (LDH; Roche Diagnostics GmbH, Mannheim,
Germany), which measures lactate dehydrogenase (LDH) leakage.
25,000 cells were seeded into a well in 96-well plates (Greiner Bio-One
GmbH, Kremsmünster, Austria) 18 h prior to exposures, except for the
outer and corner wells which were only filled with PBS to avoid the
edge effect. As recommended in the manual, medium (EMEM) supple-
mented with 1% FBS was used as assay medium to prevent LDH in sera
from increasing background absorbance. The concentrations of the test
compounds used were 10, 100, and 1000 nM for C1 and C3, and 10 and
100 nM for TCDD. Cells were exposed for 6 h and 24 h. Vehicle was
used as negative control (0.1% DMSO), and Triton X-100 (1%) as po-
sitive control. Also background controls (assay medium without cells,
with and without vehicle) were included. All exposures were performed
in triplicate in two independent experiments. Culture supernatants
were collected, and the assay performed according to the
manufacturer's instructions. Absorbances were measured with an ELISA
reader at 492 and 620 nm (absorption values were corrected with
background absorption; Multiskan Ascent, Thermo Fisher Scientific,
Waltham, MA USA). Cytotoxicity was calculated as percent, using the
following equation: 100 * (exp. value - negative control)/(positive
control - negative control). The negative control was thus at 0% cyto-
toxicity and the positive control at 100%, and the cytotoxicity of the
test compounds expressed relative to them.
2.4. MTT reduction assay
The effect of C1, C3, and TCDD on cell viability/metabolic activity
was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) reduction assay in H4IIE cells. 24,000 cells
were seeded per well in 96-well plates (Greiner Bio-One GmbH), 24 h
prior to exposures. The outer and corner wells were only filled with PBS
to avoid the edge effect. The medium used in the assay was low-glucose,
phenol red free DMEM (Gibco® DMEM, Thermo Fisher Scientific,
Paisley, Scotland, UK) supplemented with 4mM L-Glutamine (Thermo
Fisher Scientific), corresponding to the standard DMEM used for cul-
turing the cells prior to the experiment. The medium used in the ex-
periment was further supplemented with 1% FBS (Sigma-Aldrich). The
cells were exposed to vehicle, C1, C3, or TCDD (all in DMSO, final
concentration on cells 0.1%) for 6 h or 24 h at 5–6 concentrations (1,
10, 50, 100, 500, and 1000 nM C1 and C3 on cells; 1, 5, 10, 50, and
100 nM TCDD). All exposures were performed in triplicate in two in-
dependent experiments. After exposures to the test compounds, the
cells were washed once with PBS, and treated with MTT for 5 h (Sigma-
Aldrich; final concentration 1mg/ml in cell culture medium). The
medium was then gently removed, and formazan crystals dissolved in
200 μl of DMSO containing 0.1 M glycerine and 0.1M NaCl. After in-
cubation at room temperature for 10min, the absorbances were mea-
sured with an ELISA reader at 595 nm (Multiskan Ascent, Thermo
Fisher Scientific). The results were calculated as percentage over ve-
hicle controls.
2.5. Ames test
Genotoxicity was first examined by the standard plate incorporation
mutagenicity test, which was performed according to the principle of
Maron and Ames (1983). Briefly, TA98 and TA100 Salmonella Typhi-
murium strains (Institut Pasteur, Paris, France) were used, and the test
was performed both with and without metabolic activation, using 10%
S9 SD rat liver mix (Trinova Biochem GmbH, Giessen, Germany). Di-
rectly prior to plating, master mixes were prepared for each exposure
Fig. 1. Chemical structures of TCDD, the novel SAHRMs C1 and C3 used in vitro, and those of the respective, acetylated prodrugs C2 and C4 for in vivo use.
Fig. 2. The SAHRM C1 is formed in vivo by hydro-
lysis of the diacetate prodrug C2, but also in small
amounts from the drug compound laquinimod by N-
dealkylation. C3 is similarly formed in vivo from the
prodrug C4 and the drug compound tasquinimod.
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group, including (per plate): 50 μl bacteria, 100 μl histidine-biotine,
200 μl S9-mix (or NADPH-mix for plates without metabolic activation),
and 50 μl test or control compound. The master mixes were mixed by
pipetting, and 400 μl was added into each melted top agar (2.3 ml),
vortexed briefly and poured onto a plate. Water and DMSO (1.85% on
plates) were used as negative controls for both strains. As positive
controls for TA100 and TA98, respectively, NaN3 (0.04mg/ml) or 2AA
(0.2 mg/ml) were used. In addition, BaP (0.1 mg/ml) was used as a
positive control for both strains. C1 and C3 were first tested at con-
centrations of 0.375, 0.75, 1.5 and 3mg/ml, resulting in plate con-
centrations of ~17.5–170 μM. A repeat experiment was conducted at
plate concentrations of 1 nM, 100 nM, 10 μM and 1mM. The highest
plate concentration of 1mM can be considered the maximum achiev-
able dose, as it precipitated when added to the master mix. All ex-
posures were performed in triplicates in the first, and quadruplicates in
the second experiment for each compound and dose, and for all con-
trols. The plates were then incubated at 37 °C for 72 h before counting
the colonies.
2.6. Micronucleus test
Genotoxicity of C1, C3, and TCDD was further assessed by the in
vitro micronucleus test in H4IIE cells. 40,000 cells were seeded in 12-
well plates (Greiner Bio-One GmbH), 24 h prior to exposures. The
medium employed was low-glucose, phenol red free DMEM (Gibco®
DMEM, Thermo Fisher Scientific) supplemented with 4mM L-Glutamine
(Thermo Fisher Scientific) and 10% FBS, corresponding to the standard
DMEM used for culturing the cells prior to the experiment. The cells
were exposed to C1, C3, and TCDD; mitomycin C as a positive control;
and vehicle as negative control. Final concentrations on cells were: 100,
500, and 1000 nM for C1/C3; 10, 50, and 100 nM for TCDD; and
500 nM for mitomycin C. All of the compounds were dissolved in
DMSO, its final concentration on cells was 0.1%. Apart from the vehicle
control (where n=6), all exposures were performed in triplicate in a
single experiment. The exposure time was 24 h, after which the cells
were treated with cytochalasin B (4 μg/ml; Cayman Chemical, Ann
Arbor, MI USA) for 1.5–2 normal cell cycle lengths, ~28 h. Next, the
cells were washed twice with PBS and fixed with 4% paraformaldehyde
for 10–15min (in PBS, pH 6.9; Sigma) before washing again with PBS.
After the wells had dried, the cells were stained with 10% Giemsa so-
lution (Merck KGaA, Darmstadt, Germany) and micronucleus fre-
quencies analysed in 1000 binucleated cells per well.
2.7. CYP1A1 enzyme activity
CYP1A1 induction potential of C1, C3 and TCDD was assayed in the
metabolically active H4IIE rat hepatoma cell line by a luminescent
assay. CYP1A1 induction was utilised as a well-established, fairly rapid,
and highly sensitive index of AHR activation (Abraham, et al. 1988).
The aim was to compare the potency and efficacy of the novel com-
pounds with those of TCDD, and to also test whether a specific AHR
antagonist, CH-223191 (Kim, et al. 2006), is able to block any CYP1A1
induction. The experiments were performed in 96-well plates (Greiner
Bio-One GmbH, Kremsmünster, Austria). Cells were seeded at 10,000
cells/well and allowed to equilibrate for about 40 h prior to exposures.
The outer and corner wells were left without cells and filled with PBS in
order to avoid the edge effect. The cells were then exposed for 48 h to
varying concentrations of C1, C3 and TCDD (1, 10, 100, 500 pM and 1,
5, 10, 50, 100 nM, and 1000 nM for C1 and C3). Two independent ex-
periments were carried out. In addition, to test whether the selective
AHR-antagonist CH-223191 is able to block the effect of C1 in a similar
manner to that of TCDD, cells were exposed for 24 h and 48 h to 1 nM
C1 or TCDD, and a combination of 1 nM C1/TCDD and 100 nM CH-
223191.
In all experiments, the controls were exposed to the vehicle (0.1% of
DMSO in culture medium). For the 48 h treatments, culture medium
(EMEM +10% FBS) with the test compounds was changed at 24 h and
the exposures repeated. All exposures were performed in triplicates.
After exposures, CYP1A1 activity was detected with P450-Glo™
CYP1A1 Assay (Promega, Madison, WI USA) according to manufac-
turer's instructions. Subsequently, CellTiter-Glo® Luminescent Cell
Viability Assay (Promega) was used to confirm that there were no
significant differences among the wells in their numbers of viable cells
at the time of detection.
2.8. Molecular docking analysis
The three-dimensional structure of the rat AHR LBD was previously
predicted (Motto, et al. 2011) by Homology Modelling using MODEL-
LER (Webb and Sali 2016). The X-ray structures of the human HIF2α
PAS-B domain in complex with different artificial ligands (PDB id:
3H82; 3F1O; 3H7W) were used as templates. The sequence alignment
between the rat AHR (UniProt: P305615) and the template is reported
in Supplementary Fig. 1. Representative conformations of the modelled
LBD were selected among the one hundred models with the best DOPE
score (Webb and Sali 2016) by cluster analysis and refined by the
Schrödinger Protein Preparation Wizard (Schrödinger Release 2016–4:
Protein Preparation Wizard, 2016).
The molecular structures of the C1 and C3 ligands were subjected to
conformational analysis performed by ab initio Quantum Mechanical
(QM) calculations at the RHF/6-31G* level, using Jaguar (Schrödinger
Release 2016–4: Jaguar, 2016). The minimum energy conformations
were obtained by systematic search of the torsional angle C4-C3-C11-O
(Supplementary Fig. 2) with complete geometry optimization at every
step (scan every 15°). Geometry optimization was carried out in water
solution using a continuum solvent model.
Molecular Docking calculations were performed using Glide extra
precision (XP; Schrödinger Release 2016–4: Glide, 2016). To include
the part of the domain flexibility involved in ligand binding, different
modelled conformations of the AHR LBD were used for docking (en-
semble-docking technique), as previously described (Motto, et al.
2011), and a scaling factor of 0.8 was applied to the van der Waals radii
of the protein atoms (soft-docking technique). In docking calculations,
all the torsional angles of the ligands but the one associated to rotation
of the phenyl group, were restrained according to the QM results and
the QM net atomic charges were used for describing the ligand electron
distribution. One binding geometry (pose) was obtained for each ligand
in each modelled receptor conformation. To select the most favourable
pose, the binding free energies (ΔGbind) were calculated using the Mo-
lecular Mechanics Generalized Born Surface Area (MM-GBSA) approach
implemented in Prime, which includes evaluation of the solvation ef-
fects by an implicit solvent model (Schrödinger Release 2016–4: Prime,
2016). Visualization of the models was accomplished using PyMOL
(Schrödinger LLC. The PyMOL Molecular Graphics System).
2.9. Statistical analysis
Statistical analysis was performed applying the SPSS Statistics
software (IBM SPSS Statistics for Windows, Version 24.0., Armonk, NY,
USA) or GraphPad Prism (GraphPad Software, Inc., Prism 7 for
Windows, Version 7.03, La Jolla, CA USA). Statistical significance was
set at p < .05. Statistical analysis was mostly performed by one-way
ANOVA in SPSS. All distributions were normal, but the variances
proved to be non-homogeneous in some cases. However, both robust
ANOVAs, Welch and Brown-Forsythe, indicated significant outcomes
for all groups (p < .001), legitimating the approach. To compare each
group against the vehicle controls, post-hoc analysis was performed by
either Dunnett (when variances were homogenous) or Games-Howell
test (in case variances were not homogenous). The data from the mi-
cronucleus test were statistically assessed by the Cochran-Armitage test
for trend in proportions. Moreover, the dose-response data from the
CYP1A1 activity assay was analysed in GraphPad Prism using nonlinear
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regression with four-parameter logistics.
3. Results
3.1. Toxicity in vitro
3.1.1. LDH leakage assay
In the LDH leakage assay, at both 6 and 24 h time points, the
maximum cytotoxicity caused by all three test compounds was only 5%
at the concentrations tested (Supplementary Fig. 3; n=6/group).
Furthermore, no dose-dependency was evident. In pairwise compar-
isons following one-way ANOVA (p < .001), the only group that dif-
fered from the others in a statistically significant manner (p < .001)
was the positive control, 1% Triton X.
3.1.2. MTT reduction assay
A decrease in MTT reduction was observed by all three compounds,
but at differing time points and concentrations (Fig. 3). At 6 h, multiple
comparisons showed that for C1, the three highest concentrations (100,
500, and 1000 nM) differed significantly from the vehicle controls. C3
differed from the controls only at the highest concentration of 1000 nM.
TCDD did not show a reducing effect at 6 h at any of the concentrations
tested (1–100 nM).
At 24 h, a significant decrease in MTT reduction was seen with C3
likewise only at the highest concentration, while C1 did not induce a
statistically significant effect at any concentration at this time point.
With TCDD at 24 h, there was a statistically significant difference
compared with controls at the highest concentration tested, 100 nM.
Interestingly, the effect of C1 and C3 as percentage of vehicle con-
trols did not intensify dramatically between 6 h and 24 h. The max-
imum reduction percentages compared with controls were seen with C1
and C3 at 24 h and at 1000 nM, when, respectively, MTT reduction was
down to 82% and 77% of controls. At 6 h, the respective percentages at
1000 nM were 82% and 84% of controls. Furthermore, between the 6-
and 24-h time points, at concentrations up to 100 nM, the MTT re-
duction capacity of cells treated with C1 and C3 appeared to have even
slightly recovered, showing systematically a slight lessening of reduc-
tion at 24 h compared with 6 h. The statistically significant reduction by
TCDD observed at 24 h (down to 76% of controls at 100 nM of TCDD)
was clearly more intense than the effect of C1 and C3 at 100 nM or even
500 nM at either time point.
3.1.3. Ames test
In the Ames test, C1 and C3 did not appear mutagenic at the con-
centrations tested (1 nM–1mM) in either of the strains used, TA100 and
TA98. TCDD was not tested here. The number of revertants obtained
with all tested concentrations of C1 and C3 were≤~1-fold of negative
controls (complete data shown in Supplementary Tables 1. and 2.). The
negative controls (DMSO and H2O) performed consistently, and also
positive controls performed adequately (NaN3 and 2AA for TA100 and
TA98, respectively, and BaP for both strains). The indirect mutagen BaP
generated in some cases less revertants with metabolic activation than
was expected, but all positive controls differed from the negative con-
trols in a statistically significant manner.
In the TA100 strain, the numbers of revertants obtained with both
C1 and C3, at all tested concentrations, and both with and without
metabolic activation, were comparable to those of negative controls.
The only test compound group that differed significantly from the ne-
gative controls in TA100 strain was C1, which at 10 μM and in the
absence of metabolic activation, appeared to be cytotoxic. This oc-
curred only in the repeat experiment where it reduced the number of
revertants, the average fold change over negative controls was 0.45.
This effect was probably not treatment-related as it was not observed at
any of the higher concentrations tested (altogether 5 concentration le-
vels in the two experiments).
In the TA98 strain, both C1 and C3 appeared to be somewhat cy-
totoxic to the cells. In some cases in both experiments, the numbers of
revertants obtained with C1 and C3 were considerably lower than with
negative controls; however, not systematically. In the first experiment,
with all concentrations tested (17.5–170 μM) and with metabolic acti-
vation, the respective numbers of revertants with C3 and C1 were ap-
proximately 30–50% lower than with negative controls. In the first
experiment, this effect was not observed without metabolic activation.
However, in the repeat experiment, conducted with a larger con-
centration range, C1 appeared particularly cytotoxic without metabolic
activation, but only at high concentrations; at 10 μM and 1mM, average
fold changes over controls were 0.61 and 0.48, respectively.
Furthermore, in the repeat experiment and with metabolic activation,
the effect of C1 appeared less obvious, but there seemed to be a de-
creasing trend, the fold change at the highest concentration being 0.77.
For C3 in TA98, cytotoxicity was seen at the highest concentration
(1mM) with and without metabolic activation, with the respective fold
changes being 0.67 and 0.78.
3.1.4. Micronucleus test
The ability of C1 and C3 to augment micronucleus formation in the
metabolically active H4IIE cells was used as a measure of their potential
to elicit genotoxicity in vitro. For comparison, TCDD was tested si-
multaneously. The concentrations applied for C1 and C3 were 100, 500
and 1000 nM; for TCDD, they were 10-fold lower.
Fig. 3. The result of MTT assay by C1, C3, and TCDD at 6 h (left panel) and 24 h (right panel). The data are presented as percentage of vehicle control (n=6;
mean ± SD). Groups that differ from the controls in a statistically significant manner are marked with an asterisk (*p < .05, ***p≤ .001). The single asterisk at 6 h,
100 nM, refers to C1.
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In the case of TCDD and C1, a tendency towards increased frequency
of micronuclei was discernible but did not quite reach statistical sig-
nificance (Table 1). However, for C3 the Cochran-Armitage test of trend
showed a statistically significant linear trend, p= .001, with the pro-
portion cells containing micronuclei increasing as a function of con-
centration.
3.2. CYP1A1 induction potential
A luminescent assay was used to test C1, C3, and TCDD for their
potential to induce CYP1A1, a sensitive marker for AHR activation, at
48 h. The metabolically active H4IIE cell line was used for the experi-
ments, and the concentration range of the test compounds used was
0.001–100 nM (and 1000 nM for C1 and C3). In order to detect any
changes in cell numbers, the number of viable cells in each well was
examined at the end of every experiment by another luminescent assay.
No significant differences in cell viability were observed with any of the
compounds or concentrations.
In the CYP1A1 induction assay, both C1 and C3 were highly effec-
tive and potent activators of CYP1A1 (Fig. 4). The potencies of all three
compounds were similar: compared with controls, C1 and C3 induced
CYP1A1 significantly at concentrations of 100 pM and above (p≤ .009
for C1 and p≤ .013 for C3), and TCDD from 500 pM on (p≤ .008).
However, TCDD was the most potent inducer of the three. At already
500 pM, the induction by TCDD was more intense than by C1 and C3,
attaining a 50-fold difference compared with controls, while for C1 and
C3 the respective fold changes were 10 and 20. The EC50 values for C1,
C3, and TCDD were 24.1, 35.9, and 1.0 nM, respectively. The induction
potential of TCDD peaked at 50 nM and appeared to level off after that.
Interestingly, compared with TCDD, both C1 and C3 attained equiva-
lent or even higher maximum induction of CYP1A1 at the highest
concentration tested (1000 nM). Furthermore, it appears that the
maximum responses with C1 and C3 may not have been reached at
1000 nM, and that C3, possibly also C1, have therefore even higher
efficacies than TCDD.
Furthermore, we tested the ability of the selective AHR-antagonist
CH-223191 to block CYP1A1 induction by C1 and TCDD with exposure
times of 24 h and 48 h. At a concentration of 100 nM, CH-223191 was
able to completely block the effect of 1 nM C1 and TCDD at both time
points (Fig. 5).
Table 1
C1, C3, and TCDD were tested at three concentration levels in the in vitro micronucleus test. Mitomycin C was employed as a positive control.
Group Conc (nM) Micronuclei per 1000 binucleated cells Fold Trend
Replicates Average SD
Mitomycin C 500 147 162 161 157 7 10.44
Vehicle control 0.1% DMSO 12 15 17
15 3 1.0021 11 14
C1 100 24 19 20 21 2 1.40
p= .083500 25 22 24 24 1 1.58
1000 28 31 23 27 3 1.82
C3 100 25 22 30 26 3 1.71
p= .001500 30 34 26 30 3 2.00
1000 40 44 36 40 3 2.67
TCDD 10 16 12 13 14 2 0.91
p= .06850 20 16 18 18 2 1.20
100 23 26 22 24 2 1.58
Fold= Fold change vs. vehicle control.





















Fig. 4. CYP1A1 induction in H4IIE cells by C1, C3, and TCDD at the con-
centration range of 0.001–1000 nM (−100 nM for TCDD), expressed as fold
changes over controls (mean, n=3–6/group; SDs are not presented here to
improve readability, but are included in Supplementary Fig. 4).




















Fig. 5. CYP1A1 induction in H4IIE cells by 1 nM of C1 and TCDD, both without
(at left) and with (at right) the presence of 100 nM of the AHR-antagonist CH-
223191 (n= 3/group). The exposure times were 24 h and 48 h for all treat-
ments. The data are expressed as fold changes over controls, the reference line
marks vehicle control level (fold change 1.0).
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3.3. Molecular docking analysis
The AHR LBD model is shown in Fig. 6a; it adopts the classical PAS
fold with a β-sheet of 5 strands, 3 small helices and a long helical
connector. The domain has a buried internal cavity that was proved to
act as the TCDD binding region (Motto, et al. 2011, Pandini, et al.
2009).
Conformational analysis indicated a planar geometry for most of the
molecular structure of both the C1 and C3 compounds, with a value of
0° for the examined torsional angle (Supplementary Fig. 2). The planar
geometry can be attributed to an extended electron conjugation and to
two stabilizing intra-molecular H-bonds. These results are consistent
with the previous QM conformational analysis performed in vacuum by
Jansson et al. (2006).
Molecular docking simulations confirmed that both C1 (Fig. 6b) and
C3 (Fig. 6c) occupy the central region of the ligand binding cavity, si-
milarly to what is predicted for the TCDD (Fig. 6a) in the high-affinity
mouse and rat AHRs (Motto, et al. 2011). The ligand interactions that
mainly contribute to stabilization of each pose, obtained by per-residue
decomposition of the MM-GBSA ΔGbind, involve residues at the centre of
the cavity (F293, F322, I323, M346, F349, L351, Q381, shown in
Fig. 6b and c). The polar groups of both ligands are involved in intra-
molecular H-bonds, like in the unbound forms, so their stabilization
within the binding cavity is mainly due to hydrophobic interactions
(van der Waals, and aromatic stacking) with residue side-chains. C1 lies
on the same lying plane as TCDD (Fig. 7a) and both ligands reach the
most internal hydrophobic region (L306 and L313), TCDD through its
chlorine atoms and C1 through its phenyl ring. C3 shows a slightly
different lying plane (Fig. 7b) and the methoxy and the trifluoromethyl
functional groups bring the molecule nearer the helical connector, thus
translating the rest of the molecule forward compared to the other li-
gands. This slightly different placement allows the additional interac-
tions of C3 with the M338 and I377 residues. The glutamine residue at
the centre of the cavity (Q381) acts as an anchor providing inter-
molecular H-bonds.
4. Discussion
While the term SAHRM has not been unambiguously defined, it is
generally used to describe compounds that exhibit tissue- or species-
specific AHR-modulation, or induce only some of the typical responses
of AHR activation seen after dioxin exposure. SAHRMs may be natu-
rally occurring compounds, or engineered with the aim of producing
beneficial AHR-mediated effects, while lacking the toxic effects of many
dioxins.
The interest in SAHRMs is in large part due to their potential as
novel pharmacological compounds, but also because they can be va-
luable tools in further elucidating the so far incompetently understood,
multifaceted physiological roles of AHR and the underlying molecular
mechanisms. Currently, there are numerous compounds that are being
studied as potential AHR-modulating drug compounds, primarily for
treatment of different cancers and inflammatory diseases (Ehrlich and
Kerkvliet 2017, Safe, et al. 2013, 2017). Among these compounds is
laquinimod, which produces low but persistent levels of the active
N‑hydrogen metabolite C1. The mechanism of action of laquinimod is
not yet fully elucidated, but it has been recognised as an im-
munomodulatory compound (Varrin-Doyer, et al. 2014), and the mode
of action has been shown to be AHR dependent in the mouse experi-
mental autoimmune encephalomyelitis (EAE) MS model (Berg, et al.
2016, European Medicines Agency 2014, Kaye, et al. 2016).
In humans, laquinimod is metabolised by CYP3A4 to hydroxylated
and dealkylated metabolites (Tuvesson, et al. 2005). C1, also called
DELAQ (de-ethylated laquinimod), is one of these metabolites, and has
already previously been identified as a very potent AHR-activator
(European Medicines Agency 2014, Pettersson 2012). Interestingly, C1
is also a more potent inhibitor of disease development in the EAE model
than laquinimod (European Medicines Agency 2014). Furthermore,
substantially higher levels of C1 are generated in vivo from the pro-drug
C2 than from laquinimod (unpublished results). From laquinimod, for
which the human T1/2 is 71 h, C1 is continuously produced in low
amounts, and further metabolised by hydroxylation in the aniline part
via CYP1A-dependent metabolism (Tuvesson, et al. 2005). In vitro
clearance data (human hepatic extraction 84%, unpublished) and in
vivo pharmacokinetic data indicate that after C2 administration, C1 is
Fig. 6. Molecular Docking poses in the AHR model. a. The whole LBD in complex with the TCDD (red) inside the ligand binding cavity; b. The pose of C1 (green); c.
The pose of C3 (cyan). Residues that mainly contribute to the pose stabilization are shown as lines and labelled. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
Fig. 7. Comparison between the TCDD docked pose and the poses of C1 (a) and C3 (b).
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degraded in a fairly rapid manner (T1/2 in rats 1.7 h, unpublished).
Thus, administration of the prodrug C2, with efficient hydrolysis to C1,
produces quite a different exposure profile compared with laquinimod
administration, with temporal but higher levels of C1, avoiding pro-
longed and aberrant AHR activation.
In this study, we characterised the in vitro effects and in silico
binding of two novel SAHRMs, C1 and C3. Their respective prodrugs,
C2 and C4, were previously shown to be markedly less toxic than TCDD
in SD rats, while being effective AHR activators (Mahiout, et al. 2017).
Intriguingly, all of the dioxin-like effects observed in vivo fell into the
“type I" category previously demonstrated to be largely indifferent to
structural variation at the transactivation domain of the AHR in TCDD-
treated rats (Pohjanvirta, et al. 2011). Thus, these compounds may also
have wider implications to AHR research.
Here, we examined C1 and C3 in vitro for their cytotoxicity by LDH
leakage assay, their effect on metabolic activity by MTT reduction
assay, and their genotoxic potential by Ames and micronucleus tests. In
addition, we tested their AHR-inducing potential, interpreted from ac-
tivation of the xenobiotic-metabolising enzyme CYP1A1, a sensitive
biomarker for AHR activation (Abraham, et al. 1988). Finally, we
compared the binding of C1 and C3 to the rat AHR in silico, and com-
pared them with TCDD, the most toxic AHR activator.
In the LDH leakage assay, C1, C3, and TCDD were tested at 2–3
concentrations and at 6 h and 24 h exposure periods in H4IIE cells. Both
negative (vehicle) and positive controls (1% Triton X) were included,
and the cytotoxicity of the three test compounds expressed relative to
them. None of the test compounds exhibited cytotoxicity at the tested
concentrations (10 and 100 nM for TCDD, and also 1000 nM for C1 and
C3) at either of the time points. However, while being a robust method
and widely used, the LDH leakage assay only detects cytotoxicity fol-
lowing damage to the cell membrane, as LDH is released from the cy-
tosol. Therefore, it does not identify compounds that cause cytotoxicity
via other pathways. Thus, we also tested C1, C3, and TCDD by MTT
reduction assay.
In the MTT assay we examined the effect of C1, C3, and TCDD on
H4IIE cells at 5–6 concentrations (1–1000 nM, for TCDD the maximum
concentration was 100 nM) at 6 h and 24 h exposure periods; also ve-
hicle controls were included. The colorimetric MTT assay is based on
the principle that viable cells with active metabolism convert the
yellow tetrazolium dye MTT into a purple formazan product, which can
be measured. When cells die, they can no longer make this conversion.
The molecular pathways involved in disturbances in MTT reduction
into formazan are not well understood, but in controlled study condi-
tions, the amount of formazan product formed by NAD(P)H-dependent
cellular oxidoreductase enzymes is in proportion to the number of
metabolically active, viable cells (Riss et al., 2013 (Updated 2016)).
Therefore, and as the data from the test compounds were compared
with vehicle controls (100% viability and metabolic activity), the result
was interpreted to reflect a reduction in metabolic activity.
A reduction was observed by all three compounds (Fig. 3). However,
only C1 and C3 induced an effect at 6 h, when statistical analysis re-
vealed a significant effect for C1 at the three highest concentrations
starting from 100 nM, and for C3 at the highest concentration of
1000 nM. Therefore at 6 h, C1 and C3 appeared to reduce metabolic
activation more effectively than TCDD. Interestingly at 24 h, statisti-
cally significant reductions were not seen with C1 at any of the con-
centrations tested, and also with C3 only at the highest concentration of
1000 nM. Furthermore, between the 6- and 24-h time points, the MTT
reduction capacity of the cells treated with C1 and C3 (up to con-
centrations of 100 nM), appeared to have even slightly recovered.
Moreover at 24 h, TCDD induced a statistically significant reduction
already at 100 nM. It therefore appeared to reduce metabolic activation
at 24 h ~10-fold more effectively than C3. It should be noted that de-
spite the small differences in the concentrations at which the effects of
C1 and C3 reached statistical significance, overall their impacts were
highly similar.
Taken together, these data on MTT reduction support the hypothesis
we presented before (Mahiout, et al. 2017) that C1 and C3 are trans-
formed to inactive metabolites much more efficiently than TCDD, likely
at least partly explaining their considerably lower toxicity in vivo.
In the Ames test, the Salmonella typhimurium strains used were TA98
and TA100, which contain the hisD3052 and hisG46 mutations, re-
spectively (Maron and Ames 1983). The TA98 strain primarily detects
mutagens that cause frameshift mutations, while the TA100 pre-
ferentially detects mutagens causing base-pair substitutions. Only C1
and C3 were tested here, as it has been previously shown that TCDD is
not mutagenic (Thornton, et al. 2001).
Neither of the compounds appeared mutagenic at the concentration
range tested: 1 nM–1mM. The positive controls performed adequately
overall and all of them produced statistically significant positive results
compared with negative controls. However, in some cases the indirect
mutagen BaP yielded rather low numbers of revertants with metabolic
activation, indicating that the microsomal S9 mix did not work as ef-
ficiently as desired.
Some cytotoxicity was observed in the TA98 strain. The only sys-
tematic dose-responses in this respect were observed with metabolic
activation by C1 at or above ~20 μM, and by C3 at or above ~70 μM.
Moreover, cytotoxicity also manifested without metabolic activation at
the highest concentration of 1mM by both C1 and C3. Furthermore, the
plate concentrations of 1mM can be considered the maximum achiev-
able, as already at those both C1 and C3 precipitated when added to the
master mix prior to plating.
Therefore, despite some limitations in the data, the negative result
of the Ames test can be considered reliable for both compounds, par-
ticularly in the TA100 strain. It thus appears that in the Ames test, C1
and C3 do not induce base-pair substitutions, and are unlikely to induce
frameshift mutations. However, as the Ames test is only able to detect
mutagens, we also performed an in vitro micronucleus test on the H4IIE
cell line to further assess the potential for genotoxicity of these com-
pounds. S9 mix was not employed, as the cell line has retained con-
siderably high metabolic activity (Fujimura, et al. 2012). In the mi-
cronucleus assay, C3 induced a statistically significant, increasing trend
in number of micronuclei, while C1 and TCDD showed a tendency for
statistical significance (Table 1). However, the significance of the po-
sitive effect by C3 is unclear, particularly considering the small mag-
nitude of the fold-change vs. the positive control (mitomycin C) and the
similar result obtained with TCDD.
TCDD is a carcinogen, apparently as a consequence of several
complex pathways related to, at least, tumour promotion (Pitot, et al.
1980), modulation of genes related to cell proliferation and immune
system (Bersten, et al. 2013), and regulation of apoptosis (Schrenk and
Chopra 2011). However, TCDD is not a genotoxicant in vivo (Huff, et al.
1991, Meyne, et al. 1985, Nebert, et al. 2004), even though particularly
in vitro, it has occasionally appeared positive at high concentrations in
genotoxicity tests, including a micronucleus test in rat hepatocytes
(Turkez, et al. 2014). TCDD is known to cause oxidative stress (Stohs
1990), and oxidative stress may secondarily augment micronucleus
formation in vitro (Cicchetti and Argentin 2003). Therefore, it is con-
ceivable that oxidative stress is also involved in the increased micro-
nucleus frequency found for C3 in the present study. However in vivo,
following AHR-activation by AHR-agonists, subsequent induction of
metabolic enzymes, particularly CYP1A1, appears to have protective
effects due to augmented detoxification capacity, unlike in vitro
(Nebert, et al. 2004). Therefore, in order to conclude whether the effect
seen here with C3 is relevant, an in vivo micronucleus test may be ne-
cessary.
In order to study the potency and efficacy of these compounds as
AHR-activators, we had previously screened CYP1A1 induction poten-
tials of C1, C3, and TCDD after 24-h exposures, employing the same
H4IIE cell line and concentrations of 1–50 nM (Mahiout, et al. 2017).
There, both compounds, and particularly C3, induced responses close to
the same fold-range as TCDD. The result here, at 48 h exposure and also
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at higher concentrations of each of the compounds, was comparable.
This study also confirmed that C3 appears to be the (somewhat) more
effective compound of the two, as assessed by CYP1A1 induction. A
possible reason for this difference may be a higher metabolic stability of
C3, which is protected from para-hydroxylation in the aniline part by
the CF3-group, especially under conditions where CYP1A is upregu-
lated.
Moreover, both novel SAHRMs, C1 and C3, were here shown to be
similar to TCDD in both potency and efficacy. However, when com-
paring potencies and efficacies, a confounding factor may be the ex-
tremely low aqueous solubility of the compounds. Although the aqu-
eous solubilities of both C1 and C3 are very low, estimated at< 1mg/l
(approximately 3 μM), this is conceivably higher than that of TCDD
(< 1 nM; (Marple, et al. 1986). CYP1A1 induction may be dampened at
concentrations exceeding the aqueous solubility of each compound.
Another factor that can influence the activity of C1 and C3, respec-
tively, is the aforementioned metabolic stability, which may favour the
more stable C3.
These results are furthermore supported by the in vivo data with
these compounds. In SD rats, we previously showed that C2, the pro-
drug that is readily hydrolysed into C1 in vivo, is an effective inducer of
the Cyp1a1 gene at doses of 4, 20, and 100mg/kg. Even the lowest dose
tested, 4 mg/kg administered as a single ig dose, induced Cyp1a1 in-
duction by 1700-fold at 28 h after exposure, a strong early response
compared with the 350-fold increase brought about by 0.1 mg/kg TCDD
at 24 h (Mahiout and Pohjanvirta 2016). However, while the response
with TCDD intensifies over time, it appears that C2 is metabolised ra-
pidly: after single doses of 20 and 100mg/kg, Cyp1a1 induction fold
changes at 48 h and 72 h, respectively, were down to a ~100 fold in-
crease compared with controls. The MTT reduction assay results pre-
sented here further support the view that C1 and C3 are inactivated by
metabolism much more rapidly than TCDD.
Furthermore, we showed here that the AHR-antagonist CH-223191,
reported to be a selective antagonist of only dioxin-like AHR activators
(Kim, et al. 2006, Zhao, et al. 2010), was able to block CYP1A1 in-
duction by C1 in vitro as efficiently as that of TCDD. This indicates that
at least C1 may bind to the LBD of the AHR in a manner similar to that
of TCDD.
We also studied the ability of C1 and C3 to bind the AHR by in silico
methods. Simulation of ligand binding by molecular docking to the
homology model of the AHR LBD allowed prediction of both their
binding geometries and protein-ligand interactions to be similar to
those of TCDD (Fig. 6). In the docked poses, C1 and C3 show mostly
planar conformations like TCDD, thanks to the intra-molecular H-
bonds. TCDD and C1 binding poses are overlapped, especially in the
region of the aromatic rings, whereas the C3 pose is slightly translated
(Fig. 7). Despite this subtle difference, most of the stabilizing interac-
tions are maintained in the two ligands and cause similar binding af-
finities for the AHR. Moreover, most of the residues that were predicted
to be involved in the C1 and C3 stabilization (Fig. 6) belong to the
group of highly conserved residues lining the binding cavities of several
mammalian AHRs and necessary for optimal TCDD binding (“TCDD
binding-fingerprint”) (Motto, et al. 2011, Pandini, et al. 2009). There-
fore, our computational results support the hypothesis that these novel
SAHRM metabolites effectively bind to the AHR and act as its agonists.
Interestingly, a previous study found that, based on their interac-
tions with certain amino acid residues in AHR ligand-binding domain,
diverse AHR ligands could be categorized into four groups, one of
which comprised TCDD and other compounds sharing the dioxin-like
toxicity profile (Soshilov and Denison 2014). While this outcome could
be interpreted to suggest that the binding characteristics of a ligand to
the AHR LBD would be critical to its toxicity properties, our present
findings do not support this. However, the segregation was accom-
plished by mutating individual amino acids of the LBD, and only by an
identical approach could it be verified whether our novel SAHRMs in-
deed are at odds with the classification. Although the persistence of
AHR-dependent gene expression generated by metabolically stable
TCDD-like halogenated compounds is established to be crucial for the
prototypical spectrum of AHR-dependent toxicities (Bradshaw and Bell
2009), attempts to reproduce the toxicity profile of TCDD by repeated
exposure to huge doses of less stable AHR agonists have consistently
failed (Francis and Smith 1987, Neal, et al. 1979). Hence, other factors
are likely to contribute. Nevertheless, the rate of metabolism probably
plays a major part in the case of differences in toxicity between TCDD
and C1 & C3, whereas ligand binding is of low importance in this re-
gard.
Altogether, these results establish that while showing negligible in
vitro toxicity, the novel SAHRMs C1 and C3 bind to the AHR in a
manner similar to that of TCDD, and are potent and effective AHR-
agonists, in fact comparable to TCDD. Combined with our earlier results
demonstrating that they seem considerably less toxic in vivo than TCDD
(Mahiout, et al. 2017), these SAHRMs appear interesting candidates for
therapeutic uses, and could also be valuable tools in further elucidating
the multifaceted physiological roles of the AHR, and the underlying
molecular mechanisms.
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